ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Sevilla, AN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Endometrial Cancer
Carcinoma
Breast Cancer
Fallopian Tube Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near Sevilla, AN, ESP:

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer...

Enrolling
Chemotherapy-induced Thrombocytopenia
Drug: Placebo
Drug: Romiplostim

Phase 3

Amgen
Amgen

Seville, Andalusia, Spain and 139 other locations

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

This study aims to assess efficacy of Niraparib (GSK3985771) as maintenance treatment in participants with Stage III or IV ovarian cancer...

Active, not recruiting
Ovarian Neoplasms
Drug: Placebo
Drug: Niraparib

Phase 3

Tesaro
Tesaro

Sevilla, Spain and 199 other locations

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based...

Active, not recruiting
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Drug: Placebo Oral Tablet
Drug: Nivolumab

Phase 3

pharmaand

Sevilla, Spain and 237 other locations

ADP-A2M4CD8 As Monotherapy or in Combination with Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects with MAGE-A4 Positive Tumors (SURPASS)

who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen. Tumor indications include endometrial, esophageal....

Active, not recruiting
Endometrial Cancer
Esophageal Cancer
Genetic: Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks

Phase 1

Adaptimmune

Sevilla, Spain and 16 other locations

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary perito...

Active, not recruiting
Peritoneal Neoplasms
Fallopian Tube Cancer
Biological: Bevacizumab
Drug: Placebo for olaparib

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Seville, Spain and 227 other locations

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA)

This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer age....

Active, not recruiting
Breast Cancer
Biliary Cancer
Drug: Camizestrant
Drug: T- Dxd

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Seville, Spain and 67 other locations

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors th...

Active, not recruiting
Breast Cancer
Neuroendocrine Tumors
Drug: Entrectinib

Phase 2

Roche
Roche

Seville, Spain and 129 other locations

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1)

efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurred/...

Enrolling
Advanced Solid Malignancies
Drug: Datopotamab Deruxtecan (Dato-DXd)
Drug: AZD9574

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Seville, Spain and 30 other locations

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (IL Believe)

TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This is a first-i...

Enrolling
Second or Third Line (2L/3L) Cervical Cancer
Post Anti-PD-(L)1 Small Cell Lung Cancer
Drug: TransCon TLR7/8 Agonist
Drug: Trastuzumab emtansine (T-DM1)

Phase 1, Phase 2

Ascendis Pharma
Ascendis Pharma

Sevilla, Spain and 68 other locations

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors (EXCEED)

effective in participants with select advanced or metastatic solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, ...

Enrolling
Esophageal Cancer
Advanced Solid Tumor
Drug: LY4101174

Phase 1

Lilly
Lilly

Seville, Spain and 27 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems